Luijten Maartje M W, van Weelden Willem Jan, Lalisang Roy I, Bulten Johan, Lindemann Kristina, van Beekhuizen Heleen J, Trum Hans, Boll Dorry, Werner Henrica M J, van Lonkhuijzen Luc R C W, Yigit Refika, Krakstad Camilla, Witteveen Petronella O, Galaal Khadra, van Ginkel Alexandra A, Bignotti Eliana, Weinberger Vit, Sweegers Sanne, Eriksson Ane Gerda Z, Keizer Diederick M, van de Stolpe Anja, Romano Andrea, Pijnenborg Johanna M A
Department of Obstetrics and Gynaecology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.
Department of Gynaecology, Rijnstate Hospital, 6815 AD Arnhem, The Netherlands.
Cancers (Basel). 2024 May 30;16(11):2084. doi: 10.3390/cancers16112084.
Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC.
Pre-treatment tumour biopsies from 6 different sites of 80 cases treated with hormonal therapy were analysed for ER/PR-IHC expression and classified into categories 0-10%, 10-50%, and >50%. The ER pathway activity score (ERPAS) was determined based on mRNA levels of ER-related target genes, reflecting the actual activity of the ER receptor.
There was a trend towards lower PR-IHC (33% had PR > 50%) and ERPAS (27% had ERPAS > 15) in lymphogenic metastases compared to other locations ( = 0.074). Hematogenous and intra-abdominal metastases appeared to have high ER/PR-IHC and ERPAS (85% and 89% ER-IHC > 50%; 64% and 78% PR-IHC > 50%; 60% and 71% ERPAS > 15, not significant). Tumour grade and previous radiotherapy did not affect ER/PR-IHC or ERPAS.
A trend towards lower PR-IHC and ERPAS was observed in lymphogenic sites. Verification in larger cohorts is needed to confirm these findings, which may have implications for the use of hormonal therapy in the future.
晚期和复发性子宫内膜癌（EC）对激素治疗的反应可通过雌激素和孕激素受体免疫组化（ER/PR-IHC）表达来预测，PR-IHC＞50%的病例反应率为60%。ER/PR-IHC可因肿瘤位置而异，并常随肿瘤进展而丧失。因此，我们探讨了EC中ER/PR-IHC表达与肿瘤位置之间的关系。
对接受激素治疗的80例患者6个不同部位的治疗前肿瘤活检组织进行ER/PR-IHC表达分析，并分为0-10%、10-50%和＞50%三类。基于ER相关靶基因的mRNA水平确定ER途径活性评分（ERPAS），以反映ER受体的实际活性。
与其他部位相比，淋巴源性转移灶的PR-IHC（33%的PR＞50%）和ERPAS（27%的ERPAS＞15）有降低趋势（P=0.074）。血行性转移和腹腔内转移灶的ER/PR-IHC和ERPAS似乎较高（85%和89%的ER-IHC＞50%；64%和78%的PR-IHC＞50%；60%和71%的ERPAS＞15，无统计学意义）。肿瘤分级和既往放疗不影响ER/PR-IHC或ERPAS。
在淋巴源性转移部位观察到PR-IHC和ERPAS有降低趋势。需要在更大的队列中进行验证以证实这些发现，这可能对未来激素治疗的应用有影响。
Zotero 插件
